Mereo BioPharma Group plc Logo

Mereo BioPharma Group plc

Acquires and develops clinical-stage therapies for rare diseases.

MREO | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
ONE CAVENDISH PLACE, LONDON

Description

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2021-02-10 13:00
Pricing of Public Offering of ADSs
English 16.3 KB
2020-12-18 08:30
Agreement with Ultragenyx for Setrusumab
English 27.7 KB
2020-12-15 19:22
AIM Delisting
English 17.4 KB
2020-11-30 08:00
Key Dates for AIM Delisting
English 17.6 KB
2020-11-23 13:00
Mereo appoints Suba Krishnan
English 16.7 KB
2020-11-16 13:00
Virtual R&D Day
English 17.7 KB
2020-11-11 08:00
Cancellation of AIM admission
English 41.9 KB
2020-11-10 13:00
Stifel 2020 Virtual Healthcare Conference
English 15.2 KB
2020-10-20 13:00
Appointments of CFO and SVP
English 18.0 KB
2020-10-19 13:00
TIGIT IND FDA Clearance
English 19.1 KB
2020-10-12 14:44
PDMR Notification
English 13.4 KB
2020-10-09 17:05
Director/PDMR Shareholding
English 26.8 KB
2020-10-07 13:00
Registration Statement Filed with US SEC
English 20.8 KB
2020-09-29 13:00
Interim Results for 6 months ended June 30, 2020
English 406.4 KB
2020-09-28 16:21
Result of General Meeting
English 16.4 KB

Automate Your Workflow. Get a real-time feed of all Mereo BioPharma Group plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mereo BioPharma Group plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mereo BioPharma Group plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.